MEDIPOST was invited to the largest North American Rare Medicine conference, as the only Korean participant.

MEDIPOST participated in the ‘2015 World Orphan Drug Congress USA’ held on 22 to 23 April at Washington D.C. and announced the result of clinical trial on stem cell medicine etc.

MEDIPOST announced the mechanism of action and clinical status etc. for lung disease medicine ‘PNEUMOSTEM^®’ which is currently under clinical trial in U.S., and discussed joint development etc. with U.S. pharmaceutical companies.

The ‘‘World Orphan Drug Congress’’ which is the 5th occasion comprises government institutions, multinational pharmaceutical companies, bio ventures, laboratories, patient groups etc. in North America and Europe etc. and is known as the most influential event in the Orphan Drug area in North, Mid and South America.